Due to the genetic link between TSC and LAM and our previous observations of GD3 expression in Tsc2+/– heterozygote mice (16), we hypothesized that GD3 may also be an immunotherapeutic target for patients with TSC. This evidence concerns the gene TSC2 and lymphangioleiomyomatosis.